Skip to content

Advertisement

BioData Mining

What do you think about BMC? Take part in

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

OCDD: an obesity and co-morbid disease database

BioData Mining201710:33

https://doi.org/10.1186/s13040-017-0153-5

Received: 19 July 2017

Accepted: 3 November 2017

Published: 21 November 2017

Abstract

Background

Obesity is a medical condition that is known for increased body mass index (BMI). It is also associated with chronic low level inflammation. Obesity disrupts the immune-metabolic homeostasis by changing the secretion of adipocytes. This affects the end-organs, and gives rise to several diseases including type 2 diabetes, asthma, non-alcoholic fatty liver diseases and cancers. These diseases are known as co-morbid diseases. Several studies have explored the underlying molecular mechanisms of developing obesity associated comorbid diseases. To understand the development and progression of diseases associated with obesity, we need a detailed scenario of gene interactions and the distribution of the responsible genes in human system.

Results

Obesity and Co-morbid Disease Database (OCDD) is designed for relating obesity and its co-morbid diseases using literature mining, and computational and systems biology approaches. OCDD is aimed to investigate the genes associated with comorbidity. Several existing databases have been used to extract molecular interactions and functional annotations of each gene. The degree of co-morbid associations has been measured and made available to the users. The database is available at http://www.isical.ac.in/~systemsbiology/OCDD/home.php

Conclusions

The main objective of the database is to derive the relations among the genes that are involved in both obesity and its co-morbid diseases. Functional annotation of common genes, gene interaction networks and key driver analyses have made the database a valuable and comprehensive resource for investigating the causal links between obesity and co-morbid diseases.

Keywords

Functional enrichmentNAFLDType 2 diabetesEndometrial cancer

Introduction

Obesity is the new epidemic of 21st century [1]. Being a platform of numerous other diseases including type 2 diabetes, asthma, cardio-vascular disease and several cancers [25], obesity is considered as one of the most prevalent forms of conditions for the most life threatening diseases. According to the World Health Organization (2014), there are around 2 billion adults worldwide who are overweight, out of them 670 millions are nearly obese [body mass index (BMI) > 30 kg/m2], and 98 millions are severely affected by obesity [body mass index (BMI) > 35 kg/m2]. Obesity reduces life expectancy.

The number of co-morbid diseases that are associated with obesity is large and many of them are already reported in different research articles [6, 7]. According to the medical history of the patients, obesity is known to increase the risk of developing type 2 diabetes by 60%, hypertension and coronary-heart diseases by 20%, and cancers by 30% [8]. Other co-morbidities include gall-bladder disease, fatty liver and osteoarthritis [9]. Obesity is commonly known as a lifestyle driven disease. However, there exists significant evidence in literature regarding the possibility of altered molecular interactions mediated by obesity [10]. Earlier, gene network based in silico analyses have revealed the molecular links among obesity, hypertension and cardiovascular diseases, and type 2 diabetes [11]. Recent systems biology approaches have been exploring the detailed molecular interactions in obesity based on gene expression, novel marker genes, structural variants, copy numbers, polymorphisms and protein-protein interactions (PPIs) [10, 12]. Identifying the network hubs from gene and PPI networks is a very common step in the recent study for understanding the diseases and co-morbidity [13, 14]. For example, the analyses of gene network for adipose tissue and inflammatory diseases have revealed a significant overlap between the networks and their hub genes (centers) [10, 13, 14].

Thus systematic accumulation and organization of data related to association among obesity and co-morbid diseases, is necessary in the form of a database. The fast growing number of the research articles that are reporting the molecular links among obesity and co-morbid diseases, is raising the need for systematically accumulating and organizing the co-morbidity study and developing databases. The existing databases that are known to store the co-morbidity links among obesity and other diseases are mainly focusing on single disease, e.g., T1Dbase database [15] for type 1 diabetes and T2D-Db [16] for type 2 diabetes. Text-mined Hypertension, Obesity and Diabetes candidate gene database (T-HOD) is another example of disease specific co-morbid database.

T-HOD is a text mining database, containing 837, 835 and 821 candidate genes mediating hypertension, obesity and diabetes, respectively. The genes are ranked based on the number of their appearances, protein-protein interactions and single-nucleotide polymorphisms (SNPs). T2D-Db (Type 2 diabetes Database) is a comprehensive web resource that provides information of almost all known molecular components involved in T2D in human, mouse and rat. Information on candidate genes, SNPs (Single Nucleotide Polymorphism) in candidate genes or candidate regions, genome wide association studies (GWAS), tissue specific gene expression patterns, EST (Expressed Sequence Tag) data, expression information from microarray data, pathways, protein-protein interactions and disease associated risk factors or complications have been structured in T2D-Db. T1DBase contains molecular genetics and biology of type 1 diabetes (T1D) susceptibility and pathogenesis. It has a unique attribute called β cell genome atlas.

However, the need for a database for storing the information related to molecular links among obesity and all the co-morbid diseases is yet to be fulfilled by the existing databases. Here, we have designed Obesity and Co-morbid Diseases Database (OCDD) as a resource. The data for OCDD have been curated by applying a computational pipeline that performs both text mining on literature databases, such as Pubmed [17], GENECARD [18], and biological network mining on systems biology databases, such as STRING [19, 20]. OCDD is based on a pipeline that has been followed by T2D-Db and iCOD [16, 21]. The co-morbidity of diseases is explained as co-existance of two or more diseases whenever they affect the same individual [22]. Co-morbity is more significantly related to phenotype data while the real cause of co-morbidity can only be found by exploring the molecular interactions beneath the concerned diseases. Patient data are very useful in terms of establishing the co-morbidity relationship among obesity and other diseases. Hidalgo et al. have developed a dynamic network on disease pheotype (PDN) using 30 million patient data [23]. Using this network, we have validated our obesity related co-morbid disease list. Gene ontology data from DAVID [19] and GOrilla [24] have been used for annotating the functionality of groups of common genes that are associated with obesity and co-morbid diseases. The most attracting feature of OCDD is that apart from being a database of curated data from literature, and other primary and secondary data resources, it stores the results of an analysis of our systems biology based computational pipeline, which provides a clear insight of the role played by the genes that are most likely the major players in obesity and co-morbid diseases.

Database features

OCDD database has been designed for showcasing the molecular interactions on the onset of the co-morbidity of obesity and 26 diseases. Following are the key features of OCDD.
  • A comprehensive list of diseases is provided, which are repeatedly reported as co-morbid to obesity. A text mining on literature databases has been made for identifying the co-morbidity to obesity.

  • Integration of literature mining results in the disease pathway data from KEGG (Kyoto Encyclopedia of Genes and Genomes) database.

  • The co-morbidity to obesity has been measured based on statistical significance test over the search results that have been obtained from text mining and systems biology databases. A higher number of search results that are common between a disease and obesity, has been assigned a higher score for indicating a stronger co-morbidity with obesity.

  • The list of obesity associated co-morbid diseases is further validated using ϕ and RR scores available in existing Phenotypic Disease Network (PDN) [23].

  • The common genes that are known for their role in obesity and a co-morbid disease, are listed and annotated. All the biological processes, molecular functions and cellular components that are found enriched in the common gene groups, are listed in the database tables.

  • All the gene-gene interaction networks have been formed and listed for the list of common genes associated with obesity and each of the co-morbid diseases.

  • The network hub genes have been identified from the interconnections.

Method

Here we describe the method that we have adopted while designing OCDD. The patient data in OCDD has been taken from the published results of experiments conducted in Barabasi’s lab [23].

Data collection

In this present work, we have collected data by mining different databases. The flowchart (Fig. 1) depicts how and where the data have been collected from. Then the data have been analysed for finding meaningful biological connections to understand the molecular mechanism lying behind obesity and co-morbid diseases.
Fig. 1

Flowchart

The obesity associated co-morbid diseases

KEGG (Kyoto Encyclopedia of Genes and Genomes) [25] is a comprehensive data resource for disease related biological pathways and molecular functions. We have collected the names of all the diseases from KEGG database. Then we have performed text mining on PubMed [17] by using the term “obesity” and each disease name as keywords. For keyword search on PubMed, we have used Biopython [26, 27] data search utility. From nearly 22 million current entries of biomedical articles in PubMed, all the abstracts that have been matched with the disease name as a key word, have been retrieved. For computing the statistical significance of each key word search, we have performed Fisher exact test on the observed number of key word matches. The P-values from Fisher exact test have then been adjusted by Bonferroni correction for multiple test adjustment. All the diseases with the adjusted P-value < 0.05 have been identified as co-morbid to obesity in OCDD database. The procedure of calculating Fisher exact test is provided in supplementary material.

Validation with patient data

Co-morbidity refers to the co-occurrence of two diseases in a significant number of patients. Co-morbidity does not elucidate the molecular connections between co-occurring diseases. However, the modern science drives exploring the attributes that cause the co-occurrences of diseases. For this purpose, it is mandatory to validate the above obesity associated co-morbid disease list with patient data. Hidalgo et al. have developed a phenotypic disease network (PDN) on ICD-9 diseases using 30 million patient data [23]. Here, each disease in ICD-9 disease list has been analyzed for its comorbidity with other diseases, and two parameters, called ϕ value and RR score, have been calculated for understanding the degree of co-morbidity.

Consider a pool of N patients diagnosed with disease A and/or disease B. Let I A , I B and C AB be the numbers of patients diagnosed with disease A but not B, disease B but not A, and with both diseases A and B, respectively. Then C AB /N represents the chance of diagnosing both the diseases A and B in a single patient. On the other hand, I A /N and I B /N be the chances of diagnosing disease A but not B and disease B but not A in a single patient. Now, Relative Risk (RR AB ) score for diseases A and B is defined as [23]
$$ \begin{aligned} RR_{AB} &= \frac{(C_{AB}/N)}{(I_{A}/N) \times (I_{B}/N)} \\ &= \frac{N \times C_{AB}}{I_{A} \times I_{B}} \end{aligned} $$
(1)
and ϕ-correlation as [23]
$$ \phi = (RR_{AB}-1)\sqrt{\frac{I_{A} \times I_{B}}{(N-I_{A}) \times (N-I_{B})}}. $$
(2)

The term RR AB >1 indicates that the chance of diagnosing both diseases A and B in a single patient is more than the joint probability (chance) of occurring disease A but not B and disease B but not A, in a single patient. In other word, RR AB >1 and thereby ϕ>0 signify that diseases A and B occur more frequently than they do by chance.

Functional enrichment analysis

For each co-morbid disease, we have searched GENECARDS [18] database to retrieve the list of genes that are known to cause a disease as reported in biomedical literature. Sets of disease causing genes that are common with obesity genes have then been stored in OCDD as co-morbidity gene lists. Each co-morbidity gene list has then been put into the search engine of DAVID [19] for finding the functional annotation of the genes. All the biological processes, molecular functions and cellular components that are found enriched with adjusted p-values < 0.05, have been listed under function table tab in the database.

Key gene analysis

A network of genes mediating obesity and a co-morbid disease is constructed using the resources and information from STRING database. STRING database provides all known and predicted associations among proteins/genes. These associations are scored and integrated, resulting in comprehensive protein networks covering more than 1100 organisms [20]. It considers complete knowledge of all direct and indirect interactions, i.e., neighborhood, co-expression, co-occurrence, gene-fusion, homology, database incorporation, textmining and experiments [20]. Finally, the key genes or hub genes have been extracted from the aforesaid networks. Here, we consider connections strictly associated with Homo sapiens, with scores greater than 0.9, to construct the above network. In order to find the key gene of a network, the genes for each disease are sorted based on the number of connections. The highly connected genes of a disease-obesity network is considered to be the key genes. Percentage connectivity is calculated on the basis of the number of connections. For each gene, chromosome number and description of the gene are provided in the database.

Results

The functional enrichment and gene interaction networks have further been analyzed for elucidating the molecular mechanisms. The top 5% connected genes of each disease have been considered for further analysis to find the enriched GO terms.

Distribution of top 5% connected genes

The top most connected genes of each disease, i.e., the list of 225 top 5% connected genes from 26 co-morbid diseases are further analyzed on the basis of gene ontology terms (GO terms). The prominent genes are INS, LEP, VEGFA, TP53, STAT3, IL6, NFKB1. These 225 genes are clustered based on GO terms to find out the biological processes that are enriched with GO terms (Fig. 2). GOrilla is a web-based GO analysis tool with unique features to identify enriched GO terms in a list of genes. In GOrilla, the user does not require to provide any explicit target and background sets. GOrilla employs a flexible threshold in statistical approach to discover GO terms that are significantly enriched with a low p-value [24]. The list of 225 top 5% connected genes are analyzed by GOrilla. The output forms a tree of biological proesses with colour coding to understand respective biological processes and the extent of the biological processes being enriched with the genes. The result shows that the genes are mainly associated with regulation of protein kinase activity (GO:0045859), chronic inflammation response (GO:0002544,GO:0002439), sequestering of trigycerides (GO:0030730), protein metabolism (GO:0019538), positive regulation of osteoclast differentiation (GO:0045672), and response to ionizing radiation (GO:0010212). The most highly enriched process is chronic inflammatory response.
Fig. 2

Distribution of 225 genes based on GO terms

Obesity is always associated with chronic low level inflammation. The molecules from protein kinases are the agents of cross-talks among different systems present in our body. It is evident that the change in their regulation affects the end organs severely. Obesity disrupts the immunometabolic homeostasis of the system and the signaling molecules to act as the cross talkers. Sequestering of trigycerides is related to fat deposition and osteoclast differentiation is highly affected by obesity [28]. Even it is assumed that osteoporesis is nothing but obesity of bones [29]. Metabolism of proteins is also altered with the onset of obesity and hyperinsulinemia [30]. We have got no clue about how response to ionizing radiation is related to obesity.

Discussions

The gene networks of type 2 diabetes, non-alcoholic fatty liver diseases and endometrial cancer show how the genes are densely connected. These three networks have been analyzed in the following sections.

Type 2 diabetes

Type 2 diabetes is one of the prominent co-morbid diseases to obesity. A total of 561 genes have been found to be common between obesity and type 2 diabetes. Functional enrichment analysis of these 561 gene have been done. Out of 561 genes, we have found connections among 496 genes to draw the gene interaction network. The top most connected genes correspond to cell surface receptor proteins, signalling molecules, protein kinase molecules, and molecules from the immune system and hormone adiponectin. Several metabolites of fat metabolism, including acyl coA, ceramides, diacylgycerols along with FAs, act as signalling molecules. These signaling molecules activate a large number of kinases. These kinases phosphorylate serine of insulin receptor substrate (IRS) to stop insulin signalling.

Genome loci based data and population study support that highly connected genes, like ADIPOQ, MAPK3, PLCG1 and APPL1 in the database, play an important role in insulin resistance development [31, 32]. ADIPOQ or adiponcetin is an important hormone from adipocyte, whose reduction in secretion causes insulin resistance. Adiponectin signaling induces insulin sensitivity [33]. APPL1 mediates adiponectin signalling through Yin-Yang regulation [34].

Many genes involved in the immune system are present in this top connected gene list, which includes IL-6, TFN- α and IFN- γ. Previous investigations show clear connections in obesity, inflammation and type 2 diabetes [35]. Functional enrichment analysis also unveils that obesity with type 2 diabetes leads to many other diseases like colorectal cancer, bladder cancer, endometrial cancer and Alzheimer’s disease [3638].

Non alcoholic fatty liver diseases

Non alcoholic fatty liver diseases (NAFLD) form other prominent co-morbid diseases to obesity. NAFLD is a series of diseases starting from simple steatosis to steatohepatitis, followed by advanced fibrosis, and finally cirrhosis due to fat deposition in hepatocytes and subsequent increase in liver weight [39]. Simple steatosis is characterized by excessive fat accumulation, causing inflammation, cell death and scarring. Intermediate stages are defined by focal hepatic inflammation in acinar zone 3. In cirrhosis, there is presence of scar tissue and regenerative lumps that have been generated after several efforts to repair damaged tissue [39]. According to the database findings, a total of 176 genes have been found common between obesity and non-alcoholic fatty liver diseases. Out of these 176 genes, 137 genes have been found in the gene interaction network. The top most connected genes include INS, LEP, IL6, STAT3, PPARA and PPARG. Many scientific articles clearly state the link between insulin, leptin and NAFLD [4042].

Endometrial cancer

Endometrial cancer is the uncontrolled growth of inner lining of uterus, i.e., endometrim. Studies have shown that in more than 40% cases, overweight is related to endometrial cancer. Alterations in SHBG (sex hormone-binding globulin), progesterone and estrogen due to excess weight induce endometrial cancer [43]. A total of 482 genes has been found to be common between obesity and endometrial cancer. A densely connected gene interaction network has been built with 416 genes including highly connected genes, like insulin receptor gene (IRS), insulin growth factor gene (IGFBP5), intracellular adhesion molecule gene (ICAM), and many genes involved in the immune system (IL, NFKB, TLR, CASP). This proves that secretion of proinflammatory adipokines and adhesion molecules increase with the onset of obesity. These molecules play a vital role in cancer development.

Excess weight is linked with insulin resistance, which is developed as a result of increased free fatty acids in plasma. Insulin resistance affects IGF-I/IGFBP system [44, 45]. Obesity and insulin resistance change the total and bio-available sex steroids. There is a significant increase in bioactive IGF-I that inhibits systhesis of SHBG. Moreover, both insulin and IGF-1 can enhance the systhesis of androgens [46, 47]. Obesity also results in increased estrogen concentrations. Increase in androgens and estrogens, and decrease in SHBG and progesterone causes endometrial cancer [48].

Conclusion and future work

The database has been designed to explore the molecular connections of obesity and its comorbid diseases. The data have been collected using text mining, and can be used to understand the complexity of developing comobid diseases in molecular level. Some pertinent questions in this regard are: How do the diseases develop with the onset of obesity, and is the obesity a primary disease condition to develop other diseses? The answers are still not clear. A complete understanding of obesity and its comorbid diseseas will enlighten the path towards drug development. Obesity causes hypoxia in adipose tissue and hypoxia induces alteration in gene expressions. Secretion of adipokines and adipose tissue specific hormones get altered. This affects end organs and causes a large number of diseases. Adipokines, transcription factors (TFs) and microRNAs (miRNAs) act as cross talk agents in the scenario of obesity. Exploring the adipokines, TFs and miRNAs will throw more light on molecular mechanism of comorbid disease development associated with obesity. Another important issue of developing obesity and its comorbid diseases is obesogens. Obesogens are foreign chemicals that are actively involved in the development of obesity epidemic. Obesogens may alter human metabolism using multiple mode of actions. The mechanism and effects of obesogens need to be explored to completely understand obesity - a lifestyle driven disease.

Abbreviations

AMPK: 

Adenosine monophosphate-activated protein kinase

ADIPOQ: 

Gene that coded for Adiponectin in human

APPL1: 

Adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1

CASP: 

Caspases, or cysteine-aspartic proteases or cysteine-dependent aspartate-directed proteases

ER: 

Endoplasmic reticulum

FFA: 

Free fatty acids

FA: 

Fatty acids

FAT/CD36: 

FAT (fatty acid translocase), also known as CD36 (cluster of differentiation 36)

GO: 

Gene ontology

IRS: 

Insulin receptor substrate

IL, IL6: 

interleukin, interleukin 6

IFN- γ

Interferon- γ

IGF-1: 

Insulin-like growth factor-1

IGFBP: 

Insulin-like growth factor-binding protein

ICAM: 

Phosphatase and tensin homolog protein

IRE1: 

Phosphatase and tensin homolog protein

INS: 

Insulin

IL6: 

Interleukin-6

JNK: 

Phosphatase and tensin homolog protein

KEGG: 

Kyoto Encyclopedia of Genes and Genomes

LEP: 

Leptin

LPS: 

Lipopolysaccharide

MAPK3: 

Mitogen-activated protein kinase 3

NFKB1: 

Nuclear factor kappa B NAFLD: Non-alcoholic fatty liver disease

NFKB: 

Nuclear factor- κβ

OCDD: 

Obesity and co-morbid disease database

PPI: 

Protein-protein interaction

PLCG1: 

Phospholipase C, Gamma 1 gene

PTEN: 

Phosphatase and tensin homolog protein

STAT3: 

Signal transducer and activator of transcription 3- a transcription factor

SHBG: 

Sex hormone-binding globulin

T2D: 

Type 2 diabetes

TNF- α

Tumor necrosis factor- α

TLR: 

Toll-like receptor

TP53: 

Tumor protein

VEGFA: 

Vascular endothelial growth factor A

Declarations

Acknowledgements

Mrs. Indrani Ray, one of the authors, gratefully acknowledges CSIR, India for providing her a Senior Research Fellowship (09/093(0156)/2014-EMR-I).

Funding

No funding agency has funded this work.

Availability of data and materials

The datasets supporting the conclusions of this article are available at http://www.isical.ac.in/~systemsbiology/OCDD/home.php. There is no restrictions to its use by non-academics.

Authors’ contributions

IR conceived the idea, implemented and wrote the first draft of the manuscript. AB made the overall design of the database. RKD supervised the work, provided some fruitful modifications and corrected the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Machine Intelligence Unit, Indian Statistical Institute
(2)
Department of Computer Science and Engineering, University of California

References

  1. Caballero B. The global epidemic of obesity: an overview. Epidemiol Rev. 2007; 29(1):1–5.View ArticlePubMedGoogle Scholar
  2. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004; 4(8):579–91.View ArticlePubMedGoogle Scholar
  3. Shore SA. Obesity and asthma: possible mechanisms. J Allergy Clin Immunol. 2008; 121(5):1087–93.View ArticlePubMedGoogle Scholar
  4. Vague J, Vague P, Tramoni M, Vialettes B, Mercier P. Obesity and diabetes. Acta Diabetologia Latina. 1980; 17(2):87–99.View ArticleGoogle Scholar
  5. Van Gaal LF, Mertens IL, Christophe E. Mechanisms linking obesity with cardiovascular disease. Nature. 2006; 444(7121):875–80.View ArticlePubMedGoogle Scholar
  6. ORourke RW. Inflammation in obesity-related diseases. Surgery. 2009; 145(3):255–9.View ArticleGoogle Scholar
  7. Matsuzawa Y, Shimomura I, Kihara S, Funahashi T. Importance of adipocytokines in obesity-related diseases. Hormone Res Paediatr. 2003; 60(Suppl. 3):56–9.View ArticleGoogle Scholar
  8. worldobesity. http://www.worldobesity.org. Accessed Sept 2015.
  9. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. Jama. 1999; 282(16):1523–9.View ArticlePubMedGoogle Scholar
  10. Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, Zhu J, Carlson S, Helgason A, Walters GB, Gunnarsdottir S, et al. Genetics of gene expression and its effect on disease. Nature. 2008; 452(7186):423–8.View ArticlePubMedGoogle Scholar
  11. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocrine Rev. 2002; 23(5):599–622.View ArticleGoogle Scholar
  12. Schadt EE, Lamb J, Yang X, Zhu J, Edwards S, GuhaThakurta D, Sieberts SK, Monks S, Reitman M, Zhang C, et al. An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet. 2005; 37(7):710–7.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Rashid MS, Jamil H, Hontecillas R, Bassaganya-Riera J, et al. Gene regulatory network reveals oxidative stress as the underlying molecular mechanism of type 2 diabetes and hypertension. BMC Med Genomics. 2010; 3(1):45.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Paik H, Heo HS, Ban H, Cho SB. Unraveling human protein interaction networks underlying co-occurrences of diseases and pathological conditions. J Transl Med. 2014; 12:99.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Smink LJ, Helton EM, Healy BC, Cavnor CC, Lam AC, Flamez D, Burren OS, Wang Y, Dolman GE, Burdick DB, et al. T1dbase, a community web-based resource for type 1 diabetes research. Nucleic Acids Res. 2005; 33(suppl 1):544–9.Google Scholar
  16. Agrawal S, Dimitrova N, Nathan P, Udayakumar K, Lakshmi SS, Sriram S, Manjusha N, Sengupta U. T2d-db: an integrated platform to study the molecular basis of type 2 diabetes. BMC Genomics. 2008; 9(1):320.View ArticlePubMedPubMed CentralGoogle Scholar
  17. PUBMED. http://www.ncbi.nlm.nih.gov/pubmed. Accessed 10 Mar 2015.
  18. Stelzer G, Dalah I, Stein TI, Satanower Y, Rosen N, Nativ N, Oz-Levi D, Olender T, Belinky F, Bahir I, et al.In-silico human genomics with genecards. Hum Genomics. 2011; 5(6):709–17.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Dennis Jr G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA, et al. David: database for annotation, visualization, and integrated discovery. Genome Biol. 2003; 4(5):3.View ArticleGoogle Scholar
  20. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork P, et al. The string database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 2011; 39(suppl 1):561–8.View ArticleGoogle Scholar
  21. Paik H, Heo HS, Ban H-J, Cho SB. Unraveling human protein interaction networks underlying co-occurrences of diseases and pathological conditions. J Transl Med. 2014; 12(1):1.View ArticleGoogle Scholar
  22. Jakovljevic M, Ostojic L. Comorbidity and multimorbidity in medicine today: challenges and opportunities for bringing separated branches of medicine closer to each other. Psychiatr Danub. 2013; 25(Suppl 1):18–28.PubMedGoogle Scholar
  23. Hidalgo CA, Blumm N, Barabási AL, Christakis NA. A dynamic network approach for the study of human phenotypes. PLoS Comput Biol. 2009; 5(4):1000353.View ArticleGoogle Scholar
  24. Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z. Gorilla: a tool for discovery and visualization of enriched go terms in ranked gene lists. BMC Bioinformatics. 2009; 10(1):48.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, Tanabe M. Data, information, knowledge and principle: back to metabolism in kegg. Nucleic Acids Res. 2014; 42(D1):199–205.View ArticleGoogle Scholar
  26. Cock PJ, Antao T, Chang JT, Chapman BA, Cox CJ, Dalke A, Friedberg I, Hamelryck T, Kauff F, Wilczynski B, De Hoon MJ. Biopython: freely available python tools for computational molecular biology and bioinformatics. Bioinformatics. 2009; 25(11):1422–3.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Chapman B, Chang J. Biopython: Python tools for computational biology. ACM SIGBIO Newsletter. 2000; 20(2):15–19.View ArticleGoogle Scholar
  28. Cao JJ. Effects of obesity on bone metabolism. J Orthop Surg Res. 2011; 6(1):1.View ArticleGoogle Scholar
  29. Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity of bone?. Nat Clin Pract Rheumatol. 2006; 2(1):35–43.View ArticlePubMedGoogle Scholar
  30. Jensen MD, Haymond MW. Protein metabolism in obesity: effects of body fat distribution and hyperinsulinemia on leucine turnover. Am J Clin Nutr. 1991; 53(1):172–6.PubMedGoogle Scholar
  31. Avery CL, He Q, North KE, Ambite JL, Boerwinkle E, Fornage M, Hindorff LA, Kooperberg C, Meigs JB, Pankow JS, et al. A phenomics-based strategy identifies loci on apoc1, brap, and plcg1 associated with metabolic syndrome phenotype domains. PLoS Genet. 2011; 7(10):1002322.View ArticleGoogle Scholar
  32. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Investig. 2000; 106(4):473–81.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Ryu J, Galan AK, Xin X, Dong F, Abdul-Ghani MA, Zhou L, Wang C, Li C, Holmes BM, Sloane LB, et al. Appl1 potentiates insulin sensitivity by facilitating the binding of irs1/2 to the insulin receptor. Cell Reports. 2014; 7(4):1227–38.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Wang C, Xin X, Xiang R, Ramos FJ, Liu M, Lee HJ, Chen H, Mao X, Kikani CK, Liu F, et al. Yin-yang regulation of adiponectin signaling by appl isoforms in muscle cells. J Biol Chem. 2009; 284(46):31608–15.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004; 25(1):4–7.View ArticlePubMedGoogle Scholar
  36. Cohen DH, LeRoith D. Obesity, type 2 diabetes, and cancer: the insulin and igf connection. Endocr-related Cancer. 2012; 19(5):27–45.View ArticleGoogle Scholar
  37. Visscher TL, Seidell JC. The public health impact of obesity. Annu Rev Public Health. 2001; 22(1):355–75.View ArticlePubMedGoogle Scholar
  38. Luchsinger JA, Gustafson DR. Adiposity, type 2 diabetes, and alzheimer’s disease. J Alzheimers Dis. 2009; 16(4):693–704.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Alba L, Lindor K. Non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2003; 17(8):977–86.View ArticlePubMedGoogle Scholar
  40. Poordad FF. The role of leptin in nafld: contender or pretender?. J Clin Gastroenterol. 2004; 38(10):841–3.View ArticlePubMedGoogle Scholar
  41. Procaccini C, Galgani M, De Rosa V, Carbone F, La Rocca C, Ranucci G, Iorio R, Matarese G. Leptin: the prototypic adipocytokine and its role in nafld. Curr Pharm Des. 2010; 16(17):1902–12.View ArticlePubMedGoogle Scholar
  42. Nar A, Gedik O. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Acta Diabetologica. 2009; 46(2):113–8.View ArticlePubMedGoogle Scholar
  43. Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W. Hormonal interactions in endometrial cancer. Endocr-related Cancer. 2000; 7(4):227–42.View ArticleGoogle Scholar
  44. Pasquali R, Vicennati V, Bertazzo D, Casimirri F, Pascal G, Tortelli O, Labate AMM, et al. Determinants of sex hormone—binding globulin blood concentrations in premenopausal and postmenopausal women with different estrogen status. Metabolism. 1997; 46(1):5–9.View ArticlePubMedGoogle Scholar
  45. Thissen JP, Ketelslegers JM, Underwood LE. Nutritional regulation of the insulin-like growth factors. Endocrine Rev. 1994; 15(1):80–101.Google Scholar
  46. Underwood L, Thissen JP, Lemozy S, Ketelslegers JM, Clemmons DR. Hormonal and nutritional regulation of igf-i and its binding proteins. Hormone Res Paediatr. 1994; 42(4-5):145–51.View ArticleGoogle Scholar
  47. Ketelslegers JM, Maiter D, Maes M, Underwood LE, Thissen JP. Nutritional regulation of insulin-like growth factor-i. Metabolism. 1995; 44:50–7.View ArticlePubMedGoogle Scholar
  48. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk a synthetic review. Cancer Epidemiol Biomarkers Prev. 2002; 11(12):1531–43.PubMedGoogle Scholar

Copyright

© The Author(s) 2017

Advertisement